CytoDyn Reschedules Webcast from April 6 to April 7
CytoDyn Inc. (OTC.QB: CYDY) has announced a rescheduled investment community webcast set for April 7, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoDyn Inc. (OTC.QB: CYDY) has announced a rescheduled investment community webcast set for April 7, 2021. Key executives, including CEO Nader Pourhassan, will update stockholders on recent company activities, particularly focusing on COVID-19 initiatives and multiple ongoing clinical trials. The event aims to address investor inquiries, providing a platform for questions that can be submitted online. This 60-minute webcast is available on CytoDyn’s corporate website and will be archived for 30 days.
Positive
- Management will provide an update on recent COVID-19 initiatives.
- The webcast will address questions from analysts and investors, encouraging engagement.
Negative
- None.
Details
News Market Reaction – CYDY
The recorded move for CYDY in the trading session of this news was -1.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Christopher Recknor, M.D., Chief Operating Officer, will host an investment community webcast which is rescheduled one day later on Wednesday, April 7, 2021.
Management will provide a full update to its stockholders on Company activities, including recent COVID-19 initiatives and information concerning its active trials in COVID-19, NASH and cancer.
Management will provide approximately 60 minutes to address questions submitted online by analysts and investors.
Date: Wednesday, April 7, 2021
Time: 1:00 pm PT / 4:00 pm ET
Dial-In: None.
Questions:
- Prior to the webcast, questions can be submitted online to CYDY_Team@cytodyn.com
- During the webcast, questions can be submitted through the webcast link below.
This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:
https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/44397/indexl.html
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until May 7, 2021.
CONTACTS
Investors:
Michael Mulholland
Office: 360.980.8524, ext. 102
mmulholland@cytodyn.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.